Scholarlink

Hepatocellular carcinoma is one of the most frequent cancers in the world. Treatments such as immune checkpoint inhibitors or tyrosine kinase inhibitors (TKI) have some efficacy but have many adverse effects. So, more specifically targeted therapies are needed. In this study, we investigated the antitumoral effect of a tumor-penetrating and interfering peptide blocking the interaction between the proteins PP2A and SET. We analyzed the expression of phosphatase PP2A and oncoprotein SET in a group of samples from liver cancer patients with different aggressiveness scores. Expression of both proteins was found to correlate with aggressiveness of the tumor. We observed in xenograft models of hepatocellular carcinoma an antitumoral effect of iRGD-IP, a tumor-penetrating and interfering peptide blocking PP2A/SET interaction, suggesting that this peptide could be a strong candidate for development as therapeutic peptide for liver tumor treatment.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Antitumoral Effect on Liver Cancer of a Tumor-Penetrating and Interfering Peptide

  • 实验方案

  • 发表日期：

    2025年

查看全文
  • Eric Savier,
  • Pierre Tuffery,
  • Heriberto Bruzoni-Giovannelli,
  • Rachid Boudjelloul,
  • Angelita Rebollo

摘要

Hepatocellular carcinoma is one of the most frequent cancers in the world. Treatments such as immune checkpoint inhibitors or tyrosine kinase inhibitors (TKI) have some efficacy but have many adverse effects. So, more specifically targeted therapies are needed. In this study, we investigated the antitumoral effect of a tumor-penetrating and interfering peptide blocking the interaction between the proteins PP2A and SET. We analyzed the expression of phosphatase PP2A and oncoprotein SET in a group of samples from liver cancer patients with different aggressiveness scores. Expression of both proteins was found to correlate with aggressiveness of the tumor. We observed in xenograft models of hepatocellular carcinoma an antitumoral effect of iRGD-IP, a tumor-penetrating and interfering peptide blocking PP2A/SET interaction, suggesting that this peptide could be a strong candidate for development as therapeutic peptide for liver tumor treatment.